

# Alona Muzikansky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1237928/publications.pdf>

Version: 2024-02-01

123  
papers

4,185  
citations

159585  
30  
h-index

123424  
61  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 834-841.	1.6	603
2	Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	9.4	429
3	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	1.6	286
4	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	7.0	166
5	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	1.6	159
6	Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial. <i>Oncologist</i> , 2017, 22, 1528-1534.	3.7	139
7	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	7.1	133
8	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	7.0	129
9	Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 458-466.	1.1	120
10	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. <i>Neuro-Oncology</i> , 2015, 17, 862-867.	1.2	111
11	Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. <i>Annals of Neurology</i> , 2018, 83, 980-993.	5.3	110
12	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	1.6	92
13	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
14	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1490-1496.	1.5	76
15	Postoperative Intensive Care Unit Requirements After Elective Craniotomy. <i>World Neurosurgery</i> , 2014, 81, 165-172.	1.3	73
16	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	1.6	73
17	Outcome of patients with de novo versus nevus-associated melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 54-58.	1.2	71
18	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	2.9	69

#	ARTICLE	IF	CITATIONS
19	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 516-526.	1.7	67
20	Cost Analysis of a Randomized Trial of Early Palliative Care in Patients with Metastatic Nonsmall-Cell Lung Cancer. <i>Journal of Palliative Medicine</i> , 2016, 19, 842-848.	1.1	62
21	Randomized Trial of a Tailored Cognitive-Behavioral Therapy Mobile Application for Anxiety in Patients with Incurable Cancer. <i>Oncologist</i> , 2019, 24, 1111-1120.	3.7	61
22	Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1406.	7.4	61
23	Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 547-552.	1.1	57
24	Perceptions of Health Status and Survival in Patients With Metastatic Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 548-557.	1.2	48
25	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45
26	Randomized Trial of a Smartphone Mobile App to Improve Symptoms and Adherence to Oral Therapy for Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 133-141.	4.9	42
27	Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	4.1	38
28	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 4643-4649.	7.0	37
29	Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. <i>Neurology</i> , 2019, 93, e1288-e1298.	1.1	36
30	Fluorescence Polarization of Methylene Blue as a Quantitative Marker of Breast Cancer at the Cellular Level. <i>Scientific Reports</i> , 2019, 9, 940.	3.3	36
31	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	1.1	35
32	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. <i>Journal of Clinical Oncology</i> , 2014, 32, 7514-7514.	1.6	35
33	Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. <i>BMC Biology</i> , 2016, 14, 25.	3.8	33
34	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. <i>JAMA Network Open</i> , 2020, 3, e2010779.	5.9	26
35	Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. <i>Histopathology</i> , 2019, 75, 649-659.	2.9	25
36	Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 339-349.	2.6	24

#	ARTICLE	IF	CITATIONS
37	Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertility and Sterility, 2015, 103, 761-768.e1.	1.0	23
38	Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial. Contemporary Clinical Trials, 2016, 50, 54-65.	1.8	22
39	Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucopolidosis IV. American Journal of Pathology, 2016, 186, 199-209.	3.8	22
40	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	1.5	21
41	Septal bowing and pulmonary artery diameter on computed tomography pulmonary angiography are associated with short-term outcomes in patients with acute pulmonary embolism. Emergency Radiology, 2019, 26, 623-630.	1.8	21
42	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Science Translational Medicine, 2021, 13, .	12.4	21
43	Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro-Oncology, 2019, 21, 854-866.	1.2	18
44	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR<i>T790M</i>-mutant NSCLC Following Resistance to Initial EGFR<i>T790M</i> Therapy (ETCTN 9903). Clinical Cancer Research, 2021, 27, 1604-1611.	7.0	18
45	Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2013-2013.	1.6	16
46	Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer, 2015, 121, 4165-4172.	4.1	15
47	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.. Journal of Clinical Oncology, 2020, 38, 9586-9586.	1.6	14
48	Multimodal optical imaging and spectroscopy for the intraoperative mapping of nonmelanoma skin cancer. Journal of Applied Physics, 2009, 105, 102010.	2.5	13
49	Temperature induced changes in the optical properties of skin in vivo. Scientific Reports, 2021, 11, 754.	3.3	13
50	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 815-827.	2.3	12
51	The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7010-7010.	1.6	12
52	Cell release during perfusion reflects cold ischemic injury in rat livers. Scientific Reports, 2020, 10, 1102.	3.3	11
53	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. PLoS ONE, 2018, 13, e0191345.	2.5	11
54	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. Journal of Clinical Oncology, 2015, 33, 8015-8015.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465.	4.3	9
56	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2012, 30, 7524-7524.	1.6	9
57	Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With Cancer. JAMA Network Open, 2022, 5, e2216362.	5.9	9
58	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa031.	0.7	8
59	Randomized trial of early integrated palliative and oncology care.. Journal of Clinical Oncology, 2016, 34, 10003-10003.	1.6	8
60	The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.. Journal of Clinical Oncology, 2018, 36, 8544-8544.	1.6	8
61	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinaseâ€Positive Lung Cancer and CNS-Specific Relapse. JCO Precision Oncology, 2022, 6, e2100522.	3.0	8
62	End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. Journal of Palliative Medicine, 2016, 19, 1316-1319.	1.1	7
63	Isolation of intact extracellular vesicles from cryopreserved samples. PLoS ONE, 2021, 16, e0251290.	2.5	7
64	Examining the effects of stress and psychological distress on smoking abstinence in cancer patients. Preventive Medicine Reports, 2021, 23, 101402.	1.8	7
65	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. JCO Precision Oncology, 2017, 1, 1-9.	3.0	6
66	Validating Techniques for Measurement of Cutaneous Neurofibromas. Neurology, 2021, 97, S32-S41.	1.1	6
67	Randomized trial of early integrated palliative and oncology care.. Journal of Clinical Oncology, 2016, 34, 104-104.	1.6	6
68	The positive effects of early integrated palliative care on patient coping strategies, quality of life, and depression.. Journal of Clinical Oncology, 2017, 35, 92-92.	1.6	6
69	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2018, 36, e21231-e21231.	1.6	6
70	Multimodal quantitative imaging of brain cancer in cultured cells. Biomedical Optics Express, 2019, 10, 4237.	2.9	6
71	Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.. Journal of Clinical Oncology, 2016, 34, 234-234.	1.6	5
72	Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.. Journal of Clinical Oncology, 2017, 35, 10055-10055.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Randomized trial of a cognitive-behavioral therapy mobile app for anxiety in patients with incurable cancer.. Journal of Clinical Oncology, 2017, 35, 175-175.	1.6	5
74	A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.. Journal of Clinical Oncology, 2020, 38, 9595-9595.	1.6	5
75	A pilot mixedâ€methods randomized controlled trial of verbal versus electronic screening for adverse social determinants of health. Journal of the American College of Emergency Physicians Open, 2022, 3, e12678.	0.7	5
76	ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi27-vi27.	1.2	4
77	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
78	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.. Journal of Clinical Oncology, 2014, 32, 2004-2004.	1.6	4
79	A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naïve patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8088-8088.	1.6	4
80	Fluorescence Polarization Imaging of Methylene Blue Facilitates Quantitative Detection of Thyroid Cancer in Single Cells. Cancers, 2022, 14, 1339.	3.7	4
81	Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events. International Journal of Cardiology, 2021, 330, 194-199.	1.7	3
82	Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2619-2619.	1.6	3
83	Phase 2 trial of bavixumab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2030-2030.	1.6	3
84	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. Neurology, 2021, 97, S99-S110.	1.1	2
85	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.. Journal of Clinical Oncology, 2013, 31, TPS2104-TPS2104.	1.6	2
86	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 2031-2031.	1.6	2
87	Early integrated palliative care to improve family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.. Journal of Clinical Oncology, 2016, 34, 10131-10131.	1.6	2
88	A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.. Journal of Clinical Oncology, 2016, 34, 2013-2013.	1.6	2
89	Randomized trial of a cognitive-behavioral therapy mobile app for anxiety in patients with incurable cancer.. Journal of Clinical Oncology, 2017, 35, 10022-10022.	1.6	2
90	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2032-2032.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III <i>EGFR</i> mutant NSCLC.. Journal of Clinical Oncology, 2019, 37, 8507-8507.	1.6	2
92	ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. Neuro-Oncology, 2018, 20, vi19-vi19.	1.2	1
93	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS.. Neuro-Oncology, 2018, 20, vi198-vi198.	1.2	1
94	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii11-ii11.	1.2	1
95	Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.. Journal of Clinical Oncology, 2014, 32, 2020-2020.	1.6	1
96	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.. Journal of Clinical Oncology, 2014, 32, 2053-2053.	1.6	1
97	Cost analysis of a randomized trial of early palliative care (PC) in patients with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 4-4.	1.6	1
98	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2025-2025.	1.6	1
99	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2015, 33, TPS2080-TPS2080.	1.6	1
100	Rociletinib-associated cataracts in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2016, 34, 9042-9042.	1.6	1
101	The challenges of repeat biopsies at acquired resistance to EGFR TKIs.. Journal of Clinical Oncology, 2016, 34, e20571-e20571.	1.6	1
102	Improved coping to mediate the positive effects of integrated palliative care on quality of life and depression.. Journal of Clinical Oncology, 2017, 35, 10023-10023.	1.6	1
103	Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2617-TPS2617.	1.6	1
104	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8573-8573.	1.6	1
105	Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. American Journal of Clinical Pathology, 2007, 127, 642-650.	0.7	1
106	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. Journal of Clinical Oncology, 2015, 33, 8095-8095.	1.6	1
107	Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. Journal of Clinical Oncology, 2017, 35, e20041-e20041.	1.6	1
108	Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.. Journal of Clinical Oncology, 2017, 35, 230-230.	1.6	1



#	ARTICLE	IF	CITATIONS
109	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	1.2	1
110	Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21154-e21154.	1.6	1
111	Reply to I.B. Tan et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2164-2164.	1.6	0
112	AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v17.	1.2	0
113	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	1.2	0
114	HOUT-15. CIRCULATING BLOOD CELL COUNTS AS POTENTIAL BIOMARKERS OF OUTCOMES IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi116.	1.2	0
115	NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI. <i>Neuro-Oncology</i> , 2020, 22, ii148-ii148.	1.2	0
116	Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.. <i>Blood</i> , 2005, 106, 3290-3290.	1.4	0
117	Relationship between whole-body tumor burden and quality of life in patients with neurofibromatosis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6136-6136.	1.6	0
118	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2027-2027.	1.6	0
119	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii138-ii139.	1.2	0
120	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii40.	1.2	0
121	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
122	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	0
123	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024.	1.6	0